The Initiation, but Not the Persistence, of Experimental Spondyloarthritis Is Dependent on Interleukin-23 Signaling

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

(2017) Brian G Feagan et al.   LANCET

2017 ACR/ARHP Annual Meeting Abstract Supplement

(2017)   Arthritis & Rheumatology

Innate Immune Activation Can Trigger Experimental Spondyloarthritis in HLA-B27/Huβ2m Transgenic Rats

(2017) Melissa N. van Tok et al.   Frontiers in Immunology

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease

(2016) Stephan R Targan et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

(2016) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

(2016) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

2016 ACR/ARHP Annual Meeting Abstract Supplement

(2016)   Arthritis & Rheumatology

Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up

(2015) R.G. Langley et al.   BRITISH JOURNAL OF DERMATOLOGY

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

(2015) K. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability

(2015) Jacob S. Lee et al.   IMMUNITY

Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation

(2015) Joseph R. Maxwell et al.   IMMUNITY

Neutralizing IL-23 Is Superior to Blocking IL-17 in Suppressing Intestinal Inflammation in a Spontaneous Murine Colitis Model

(2015) Ran Wang et al.   INFLAMMATORY BOWEL DISEASES

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

(2015) James G. Krueger et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

(2015) Dominique Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis

(2015) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

(2015) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

2015 ACR/ARHP Annual Meeting Abstract Supplement

(2015)   Arthritis & Rheumatology

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

(2014) Christopher Ritchlin et al.   ANNALS OF THE RHEUMATIC DISEASES

Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)

(2014) Denis Poddubnyy et al.   ANNALS OF THE RHEUMATIC DISEASES

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-23 Mediates the Intestinal Response to Microbial β-1,3-Glucan and the Development of Spondyloarthritis Pathology in SKG Mice

(2014) Helen Benham et al.   Arthritis & Rheumatology

Tristetraprolin regulation of interleukin 23 mRNA stability prevents a spontaneous inflammatory disease

(2013) Céline Molle et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Synovial Fibroblasts Directly Induce Th17 Pathogenicity via the Cyclooxygenase/Prostaglandin E2 Pathway, Independent of IL-23

(2013) S. M. J. Paulissen et al.   JOURNAL OF IMMUNOLOGY

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

(2013) Iain B McInnes et al.   LANCET

How Cytokine Networks Fuel Inflammation: Interleukin-17 and a tale of two autoimmune diseases

(2013) Dominique L. P. Baeten et al.   NATURE MEDICINE

IL-23 Dependent and Independent Stages of Experimental Arthritis: No Clinical Effect of Therapeutic IL-23p19 Inhibition in Collagen-induced Arthritis

(2013) Ferry Cornelissen et al.   PLoS One

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

(2012) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

Autoimmune epididymoorchitis is essential to the pathogenesis of male-specific spondylarthritis in HLA-B27-transgenic rats

(2012) Joel D. Taurog et al.   ARTHRITIS AND RHEUMATISM

Relationship between inflammation, bone destruction, and osteoproliferation in the HLA-B27/human β2-microglobulin-transgenic rat model of spondylarthritis

(2012) Leonie M. van Duivenvoorde et al.   ARTHRITIS AND RHEUMATISM

β-glucan triggers spondylarthritis and Crohn's disease-like ileitis in SKG mice

(2012) Merja Ruutu et al.   ARTHRITIS AND RHEUMATISM

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

(2012) Wolfgang Hueber et al.   GUT

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells

(2012) Jonathan P Sherlock et al.   NATURE MEDICINE

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-23 Is Critical for Induction of Arthritis, Osteoclast Formation, and Maintenance of Bone Mass

(2011) I. E. Adamopoulos et al.   JOURNAL OF IMMUNOLOGY

Interleukin-23 Drives Intestinal Inflammation through Direct Activity on T Cells

(2010) Philip P. Ahern et al.   IMMUNITY

Dual roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis

(2010) Y. Esaki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reciprocal regulation of IL-23 and IL-12 following co-activation of Dectin-1 and TLR signaling pathways

(2009) Kevin M. Dennehy et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY